$CHRS

Coherus Oncology (CHRS) shares rose more than 15% after the company announced a special dividend of contingent value rights (CVRs) tied to monetizing remaining biosimilar assets. CVRs will be distributed pro rata to stockholders of record Sept. 30, 2026, with distribution scheduled for Oct. 7, 2026. Coherus reported Q2 2026 net loss from continuing ops of $33.3M and LOQTORZI revenue up 37% to $13.6M.

Coherus Oncology, Inc. (CHRS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement ​ Senior Secured Term Loan ​ On August 12, 2026, Coherus Oncology, Inc. (the “Company”), together with certain wholly owned subsidiaries of the Company (collectively with the Company, the “Borrowers”), entered into a Loan and S

Coherus Oncology (CHRS) reported Q2 2026 results on an earnings call. LOQTORZI net revenue was $13.6M, up 15% sequentially and 37% YoY. Full-year LOQTORZI guidance is $57M to $62M. Total net revenue from continuing ops was $14.3M. Cash and marketable securities were $105.3M at June 30, 2026.

Coherus Oncology (NASDAQ:CHRS) reported Q2 updates on tagmokitug and LOQTORZI during an earnings call. It said preliminary head and neck response and biomarker findings are based on limited patients, with formal disclosure expected in October. LOQTORZI net sales were $13.6M, up 15% sequentially. Full-year 2026 LOQTORZI revenue guidance is $57M to $62M; 2026 operating expenses $170M to $175M.

Coherus Oncology, Inc. (CHRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update ​ – LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 – ​ – Clinical data continue to mature across programs with emerging evidence of activity with tagmokit

Coherus Oncology and Zumutor Biologics said they will collaborate on a Phase 1 trial combining ZM008, an NK checkpoint anti-LLT1 antibody, with LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor. The study will enroll up to 45 patients in the U.S. across dose-escalation and expansion cohorts for several solid tumors, including CRC, HNSCC, NSCLC, ccRCC and urothelial cancers.

Coherus Oncology Inc. (NASDAQ: CHRS) is identified as a top penny stock with potential to triple money, following its Q4 2025 earnings report. The company showed progress with increased LOQTORZI sales and significant debt reduction, signaling a transition towards an oncology-focused business. Management anticipates further growth through revenue, partnerships, and clinical catalysts in 2026 for its immunotherapy pipeline.

DelveInsight's report highlights significant advancements in the Metastatic Hepatocellular Carcinoma (HCC) pipeline, with over 20 companies and 25+ pipeline drugs in development. Key clinical trial updates include Coherus Oncology Inc.'s Phase 2 trial for SRF388 and AstraZeneca's Phase I/II study for AZD5851. The report details several promising emerging drugs like CS1003, Casdozokitug, TTI-101, and ST316, emphasizing the robust research efforts to address this challenging cancer.

Coherus BioSciences (CHRS) is expected to report a significant decline in EPS and revenue for Q4, with analysts forecasting -$0.31 EPS and $14.09 million in revenue. The biotechnology company, focusing on oncology, shows financial distress indicators like a negative Altman Z-Score and declining revenue growth. Despite the financial challenges, its strategic focus on expanding the oncology pipeline offers potential long-term growth, though near-term risks remain significant.

Coherus Oncology (CHRS) delivered earnings and revenue surprises of -3.13% and -5.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?